Maria Hafez

Honored to Represent St. Luke's University Health Network at the Precision Oncology Summit 2026 - @HafezMaria oncodaily.com/voices/maria-h… #Cancer #Oncology #Health #Medicine #OncoDaily @CancerWorldmag

Lourdes was diagnosed with metastatic (stage IV) breast cancer at the age of 25 & is now participating in one of our clinical trials. Their story was featured in the @AACR's #CancerProgressReport 2024: cancerprogressreport.aacr.org/report/survivo… #BreastCancerAwarenessMonth #bcsm #MBC @HafezMaria

Dr. O'Regan gives us a new algorithm for 2nd line ER+ #bcsm 🔺Profiling is 🔑 - it's complicated 🗺️ 🔺We have multiple options 👍🏼 🔜 I'm still waiting for better endocrine backbones- they're coming! #ASCO24

🚨 Happening Now at #ASCO24! 🚨 Dr. Noha Soror @noha_soror is now presenting the Program Directors and Leadership Committee of ASCO IMG CoP! 🌟 Don't miss this insightful session on leadership and program development! @ASCO @ASCOTECAG @OncoAlert

“Where it all started “ by ⁦@thenasheffect⁩ during #IMG ⁦@ASCO⁩ coP session on beautiful #Kashmir #ASCO24 ⁦@NazliDizman⁩ ⁦@ZiadBakouny⁩

Maria Hafez, MD, discusses factors such as HER2 status, lymph node negativity, and risk stratification that influence the selection of adjuvant approaches in early-stage HER2+ breast cancer, and more. @KimmelCancerCtr @JeffersonUniv #OncLiveSOSS #bcsm onclive.com/view/biomarker…

Maria Hafez, MD, spotlights the KATHERINE trial in HER2-positive breast cancer, expanding on the respective toxicity profiles of T-DM1 and trastuzumab that were identified in an exploratory safety analysis of the trial. @KimmelCancerCtr #bcsm onclive.com/view/explorato…

Maria Hafez, MD, spotlights updated outcomes with T-DM1 in patients with residual invasive HER2-positive breast cancer after neoadjuvant treatment and surgery, and more. @KimmelCancerCtr #bcsm onclive.com/view/explorato…

#SABCS2023 Good news for young BRCA patients who want to get pregnant 👏 For more details 👇 jamanetwork.com/journals/jama/… @SABCSSanAntonio @KimmelCancerCtr

#SABCS2023 More exciting news for mHR+ve patients with TROPION BREST01. Dato-Dxd, after 1-2 lines of therapy, improved - PFS 6.9 vs 4.5 mo (HR 0.64) comparing to chemotherapy Not only that, 💊The time for subsequent treatment is 8.2 vs 5.0 mo. 🩺 Less side effects with Dato 💪🏻 better quality of life. More choices! More Hope! @SABCSSanAntonio @AACR @OncLive @KimmelCancerCtr

#SABCS23 Day 2 Highlights #CommunityOnc: HR+ 1. Update #CM7FL + #KN756 2. #MONARCH3 3. #HER2CLIMB02 (Her2+) 4. Role of Anthracyclines 5. #OLAnzaPiNE (all solid tumors) 1/6 #bcsm #OncTwitter @SABCSSanAntonio @AACR @UTHealthSAMDA #BreastCancer #MedTwitter @ThanksCancer

#SABCS23 🚨HER2CLIMB-02 trial presented by Sara Hurvitz, Second Trial includes active brain mets in HER2+v BC patients. - TDM-1 +\- Tucatinib in second-line settings. - PFS 9.5 vs 7.4 (HR 0.76). If brain Mets are present, then PFS is 7.8 vs 5.7 (HR 0.64) (40% of the population) - OS immature. Keep 👀on LFT ❓Where does it fall in the treatment algorithm? Nice slide presented by @valentinaguarn. @SABCSSanAntonio

#SABCS2023 Great presentation by Laura Hupper for neoadjuvant IO ( Pembro KN 756 and NIVO in Checkmate 7FL) improved PCR in high risk patients with HR+ve / HER2 -ve breast cancer patients.🎯 - awaiting EFS result! IMpassion030 result 🚨No benefit of adding Atezo to chemotherapy in the adjuvant setting for ealry syage TNBC @SABCSSanAntonio

@SACS2023 Special Session 1 is done. FDA approved three medications for mBC. 1. Elacestrant: With ESR- 1 mutation 2. T-DXd: low HER2 3. Capivasertib: + Fulvestrant: with PIK3CA/AKT1/PTEN mutations. HER2- HR+ patients More choices! More hope! @SABCSSanAntonio